135 related articles for article (PubMed ID: 31053508)
1. Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
Geng A; Cui H; Zhang L; Chen X; Li H; Lu T; Zhu Y
Bioorg Med Chem Lett; 2019 Jul; 29(13):1605-1608. PubMed ID: 31053508
[TBL] [Abstract][Full Text] [Related]
2. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
[TBL] [Abstract][Full Text] [Related]
5. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
He S; Dong G; Li Y; Wu S; Wang W; Sheng C
Angew Chem Int Ed Engl; 2020 Feb; 59(8):3028-3032. PubMed ID: 31943585
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
Yu Y; Ran D; Jiang J; Pan T; Dan Y; Tang Q; Li W; Zhang L; Gan L; Gan Z
Bioorg Med Chem Lett; 2019 Aug; 29(16):2136-2140. PubMed ID: 31272794
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
11. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity.
Mackwitz MKW; Hesping E; Eribez K; Schöler A; Antonova-Koch Y; Held J; Winzeler EA; Andrews KT; Hansen FK
Eur J Med Chem; 2021 Feb; 211():113065. PubMed ID: 33360801
[TBL] [Abstract][Full Text] [Related]
13. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
14. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.
Hesham HM; Lasheen DS; Abouzid KAM
Med Res Rev; 2018 Sep; 38(6):2058-2109. PubMed ID: 29733427
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.
Karati D; Mukherjee S; Roy S
Med Oncol; 2024 Mar; 41(4):84. PubMed ID: 38438564
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Huang Y; Dong G; Li H; Liu N; Zhang W; Sheng C
J Med Chem; 2018 Jul; 61(14):6056-6074. PubMed ID: 29940115
[TBL] [Abstract][Full Text] [Related]
20. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
